|
|
|
|
|
Page 2
Pancreatic cancer - this disease progresses very rapidly, and is invariably fatal. The mean survival time after diagnosis is 3 to 6 months. A small Phase I pilot study using proteasome inhibitor appears very promising. A combination of bortezomib with gemcitabin resulted in a significantly increased survival time.
Colon and esophageal cancers - preliminary Phase I clinical trials indicated that many patients showed stability of their cancers and clinical responses. References 1. Adams, J. Development of the Proteasome Inhibitor PS-341. The Oncologist, Vol. 7, No. 1, pp. 9-16 (February 2002) 2. Adams, J., et. al. Proteasome Inhibition: A New Pathway in Cancer Therapy. Medscape CME, June 13, 2003 Go To Page: 1 2
The copyright of the article Proteasome Inhibitors for Cancer Therapy - Page 2 in Cancer Treatment is owned by . Permission to republish Proteasome Inhibitors for Cancer Therapy - Page 2 in print or online must be granted by the author in writing.
|
|
|
|